

10/500050

DT09 Rec'd PCT/PTO 25 JUN 2004

Express Mail Label No. EV438969753US
Docket No. 61535 (46342)

U.S. PATENT APPLICATION

Title: METHOD OF QUANTIFYING NUCLEIC ACID AND KIT FOR
QUANTIFYING NUCLEIC ACID

Inventors: Makoto KOBAYASHI, Toshimitsu ARAI, Fumika MATSUMURA

Attorney: David G. Conlin (Reg. No. 27,026)
John B. Alexander, Ph.D. (Reg. No. 48,399)
EDWARDS & ANGELL, LLP
P.O. Box 55874
Boston, MA 02205
Telephone: (617) 439-4444

DESCRIPTION

DT09 Rec'd PCT/PTO 25 JUN 2004

METHOD OF QUANTIFYING NUCLEIC ACID AND KIT FOR QUANTIFYING
NUCLEIC ACID

5

Background Art

The present invention relates to a standard preparation that is used to draw up a calibration curve used to quantify a specific target nucleic acid in a sample, a method for quantifying a nucleic acid thereby, or a quantitative kit. The present invention also relates to a method for diagnosing a specific disease by using the nucleic acid quantitative method or quantitative kit, or a medicine comprising the specified gene DNA or the gene product.

Since it is possible to detect a small amount of a target nucleic acid after amplifying it exponentially by using the PCR (polymerase chain reaction) method, the PCR method is largely used in the fields of expression analysis of genes, diagnosis of disease, detection of food containing recombinant genes or determining the presence of recombinant genes in natural foods. The PCR method is, for example, disclosed in US Patent 4,683,195, US Patent 4,683,202 and US Patent 4,965,188 and others in detail. The general PCR method can easily detect a small amount of a target nucleic acid by reacting the sample that may contain the target nucleic acid with an amplification reagent comprising a pair of oligonucleotide primer corresponding to the target nucleic acid, reaction substrate (deoxynucleotide triphosphate), and DNA polymerase and the like, and exponentially amplifying the target nucleic acid.

Additionally, the TaqMan method is known, which uses a fluorescent probe and the like in PCR method as a method for quantifying a specific mRNA with high accuracy. For example, Patent Kokai 2001-204483 discloses a TaqMan method to quantify hTERT mRNA.

Further, a technique using an internal standard has been developed to improve the accuracy in quantifying a small amount of a target nucleic acid, for example, as disclosed by the publication of Patent Kokai H11-123095. This publication discloses a method for quantifying a target nucleic acid in which a plasmid including a DNA sequence that behaves as an internal standard is used with an amplification reagent, and the cRNA produced by this plasmid is used as an internal standard.

By the above method, it is possible to quantify a target nucleic acid more accurately than with a method that does not use an internal standard. However, since the RNA as

an internal standard is obtained from a plasmid in a reactor by this method, a specific and constant amount of RNA cannot always be prepared depending on the storage condition of the reagent, the reaction condition, and other factors. Furthermore, a standard preparation produced by the conventional enzyme or organism is complex and is often difficult to prepare. In order to prepare the standard preparation by the conventional method, it is necessary to extract genome DNA or RNA or mRNA from cells, organs or virus of the desired species on the basis of the sequence information and to enzymatically or biologically synthesize the segment of the desired gene or DNA or RNA having those characteristics. Moreover, the species used as materials include some that are difficult to obtain or have strong pathogens. Furthermore, in the preparation of the standard preparation, enzymes extracted from organisms or the organisms per se are used, which lead to introduction of biological contaminants that prevent highly accurate quantification.

Therefore, if there were provided a standard preparation that does not have the above disadvantages, i.e., a standard preparation obtainable by a convenient method, and having no biological contaminant, or a method capable of quantifying a target nucleic acid with a high accuracy using the standard preparation, then it would be useful in the fields of identification of disease genes, diagnosis of specific diseases, treatment of diseases, or the like.

Disclosure of the Invention

Therefore, the present invention provides a standard preparation, a method for quantifying the nucleic acid, a kit for quantifying nucleic acid, a method for diagnosis of a specific diseases, and the like, as described below.

(1) A standard preparation useful to quantify or detect a specific target nucleic acid in a sample, comprising a synthetic polynucleotide obtained by chemical synthesis.

(2) The standard preparation of (1), wherein the synthetic polynucleotide is RNA, DNA or a modification thereof.

(3) The standard preparation of (1), wherein the synthetic polynucleotide is RNA or DNA.

(4) The standard preparation of (3), which is a sense strand if the synthetic polynucleotide is RNA, or which is an antisense strand if the synthetic polynucleotide is DNA.

(5) The standard preparation of (1), wherein the synthetic polynucleotide is a synthesized part of the target nucleic acid, and the number of nucleotides is between 60 and 200.

(6) A kit for quantifying nucleic acid comprising the standard preparation of any one of claims (1) to (5).

(7) A kit for quantifying nucleic acid comprising the standard preparation of any one of claims (1) to (5) and at least one pair of primers.

5 (8) The kit of (7), additionally comprising a fluorescent probe or a phosphorylated probe.

(9) The kit of (8), additionally comprising a DNA polymerase.

(10) The kit of (9), additionally comprising a reverse transferase.

10 (11) A kit for quantifying nucleic acid to quantify multiple target nucleic acids, wherein an amplification reagent comprising a pair of primers corresponding to the target nucleic acid is loaded with at each reaction site of a reactor having multiple reaction sites, and an amplification reagent comprising the standard preparation of any one of claims 1 to 5 and a pair of primers corresponding to the standard preparation is loaded at a reaction site which is not loaded with a pair of primers corresponding to the target nucleic acid.

15 (12) The kit for quantifying nucleic acid of (11), which is used to diagnose the specific disease, and wherein the multiple target nucleic acids are DNA or mRNA related to the specific disease.

(13) The kit for quantifying nucleic acid of (11), which is used to detect recombinant DNA in food, and wherein the multiple target nucleic acids are recombinant DNA contained in genetically-modified food.

20 (14) A method for quantifying a specific target nucleic acid in a sample, which comprises adding an amplification reagents comprising at least one pair of primers corresponding to a target nucleic acid to the sample, adding to a chemically synthesized polynucleotide as a standard preparation, an amplification reagent comprising a pair of primers corresponding to the synthesized polynucleotide, carrying out each amplification reaction, measuring the
25 amounts of the amplified standard preparation and the amplified target nucleic acid, and calculating the amount of the target nucleic acid before amplification according to the information obtained by the measurements.

(15) The method of (14), wherein the synthetic polynucleotide is RNA, DNA or a modification thereof.

30 (16) The method of (14), wherein the synthetic polynucleotide is RNA.

(17) The method of (16), wherein the synthetic polynucleotide is a sense strand.

(18) The method of any one of (14) to (17), wherein the synthetic polynucleotide is a synthesized part of the target nucleic acid, and the number of nucleotides is between 60 and 200.

35 (19) The method of any one of (14) to (18), wherein the sample is an mRNA sample of

human or other animal origins.

(20) The method of (19), wherein the amplification reagent additionally comprises a fluorescence probe or a phosphorylated probe.

(21) The method of (20), wherein the amplification reagent additionally comprises a DNA
5 polymerase.

(22) The method of (21), wherein the amplification reagent additionally comprises a reverse transferase.

(23) The method of any one of (20) to (22), wherein (1) a probe portion of a fluorescence
10 probe or a phosphorylated probe contained in the amplification reagent comprising at least one pair of primers corresponding to a target nucleic acid, is a probe consisting of the nucleic acid of the region between the pair of primers in the target nucleic acid, and (2) a portion of the a fluorescence probe or a phosphorylated probe contained in the amplification reagent comprising the pair of primers corresponding to the synthetic polynucleotide, is a probe consisting of the nucleic acid of a region between the pair of
15 primers in the synthetic polynucleotide.

(24) The method of (23) to measure the amount of the amplified standard preparation and the amount of the amplified target nucleic acid using the fluorescence intensity of the fluorescent substance released from the fluorescence probe or the phosphorylated probe by DNA polymerase or the amount of phosphate group as an index.

20 (25) A method for analyzing SNPs which uses the kit of (11) or the method of (14).

(26) A method for diagnosing a specific disease, which uses the kit of (12) or the method of (14).

(27) A method for determining if food contains recombinant gene DNA or not, which uses the kit of (13) or the method of (14).

25 (28) A medicine which is specified by the kit of (12) or the method of (26), which comprises a gene DNA in which expression is distinctively increased or reduced in a certain cell or tissue, or a gene product thereof, or an agonist, antagonist, or antibody against the gene product.

The present invention will be described in detail below.

The Best Mode for Carrying Out the Invention

(Standard Preparation)

The standard preparation of the present invention is used to quantify or detect a specific target nucleic acid in a sample and is characterized by comprising a synthetic
35 polynucleotide obtained by chemical synthesis. The "standard preparation" means a

standard preparation used to draw up a calibration curve used to calculate the amount of a target nucleic acid before amplification or used to detect a specific nucleic acid sequence such as an SNP. The methods of drawing the calibration curve and calculating the amount of target nucleic acid before amplification are described later.

5 The standard preparation used in the present invention is a synthetic polynucleotide, and is preferably a single strand or double strand RNA obtained by chemical synthesis, a single strand or double strand DNA, or a modification thereof. The "modification" means those having a portion chemically modified, for example: (1) those having a chemically modified purine ring and/or pyrimidine ring (for example, those having
10 methylated purine or pyrimidine ring or acylated purine or pyrimidine ring), or those comprising other heterocyclic ring, (2) those having a chemically modified sugar portion (for example, those wherein one or more hydroxyl groups are substituted with halogen or aliphatic groups, or substituted with a functional group such as ether or amine), (3) those with biotinylation, (4) those with FITC conjugation, (5) those modified with
15 digoxigenin, (6) those with phosphorylation, (7) those modified with peroxidase, (8) those modified with alkaliphosphatase, (9) those modified with luciferase.

Since it is possible to obtain entirely by chemical synthesis the needed amount of the desired polynucleotide having a single chemical structure, a chemical synthesized polynucleotide is used in the present invention.

20 The standard preparation of the present invention is, preferably, a single strand obtained by chemical synthesis, more preferably, a sense strand obtained by chemical synthesis. Further, in the case of using a single chemically synthesized strand, an antisense strand is preferable. Because using a single strand rather than a double strand allows the standard to more closely resemble the condition of the nucleic acid being
25 quantified, the accuracy of the quantification is improved.

The synthesized polynucleotide of the present invention may be a synthesized polynucleotide having the same nucleic acid sequence as the target nucleic acid or a portion thereof, and having the similar sequence of the standard preparation obtained by conventional biosynthesis. Such standard preparations include, for example, 18S
30 Ribosomal RNA, Acidic Ribosomal Protein, β -actin, Cyclophilin, Glyceraldehyde-3-phosphate dehydrogenase, Phosphoglycerokinase, β 2-microglobulin, β -Glucuronidase, Hypoxanthine Ribosyl Transferase, Transcription Factor IID/TATA Binding Factor, Transferrin Receptor, and the like.

It is easy for a skilled artisan to synthesize a polynucleotide for the standard
35 preparation of the present invention by chemical synthesis on the basis of the known

sequence. Synthesis methods of known polynucleotides include, for example, the phosphoamidite method, H-phosphate method, and other known methods.

The phosphoamidite method is disclosed, for example, in Wu, T., Ogilvie, K. K., and Pon, R. T. (1989) "Prevention of chain cleavage in the chemical synthesis of 2'-O-silylated oligoribonucleotides" Nucl. Acids Res. 17, 3501-3517; Stawinski, J., Stromberg, R., Thelin, M., and Westman, E. (1988) "Studies on the t-butyldimethyl-silyl group as 2'-O-protection in oligoribonucleotide synthesis via the H-phosphonate approach" Nucl. Acids Res. 16, 9285-9288; Scaringe, S. A., Franklyn, C., and Usman, N. (1990) "Chemical synthesis of biologically active oligoribonucleotides using b-cyanoethyl protected ribonucleoside phosphoramidites" Nucl. Acids Res. 18, 5433-5441; Chaix, C., Molko, D. and Teoule, R. (1989) "The use of labile base protecting groups in oligoribonucleotide synthesis" Tetrahedron Lett. 30, 71-74; Gasparutto, D., Livache, T., Bazin, H., Duplaa, A. M., Guy, A., Khorlin, A., Molko, D., Roget, A., and Teoule, R. (1992) "Chemical synthesis of a biologically active natural tRNA with its minor bases" Nucleic Acids Res. 20, 5159-5166; Vinayak, R., Anderson, P. McCollum, C., and Hampel, A. (1992) "Chemical synthesis of RNA using fast oligonucleotide deprotection chemistry" Tetrahedron Lett. 31, 7269-7272; and the like. Further, H-phosphate method is, for example, disclosed in Garegg, P. J., Regberg, T., Stawinski, J. and Stromberg, R. (1985). Formation of internucleotidic bonds via phosphonate intermediates. Chem. Scripta 25, 280-282 ; Garegg, P. J., Regberg, T., Stawinski, J. and Stromberg, R. (1986). Nucleoside hydrogenphosphonates in oligonucleotide synthesis. Chem. Scripta 26, 59-62 ; Garegg, P. J., Lidh, I., Regberg, T., Stawinski, J. and Stromberg, R. (1986) ; Nucleoside H-phosphonates. III. Chemical synthesis of oligodeoxyribonucleotides by the hydrogenphosphonate approach. Tetrahedron Lett. 27, 4051-4054 ; Froehler, B. C., Ng, P. G., and Matteucci, M. D. (1986). Synthesis of DNA via deoxynucleoside H-phosphonate intermediates. Nucleic Acids. Res. 14, 5399-5407 ; Froehler, B. C., and Matteucci, M. D. (1986). Nucleoside H-phosphonates : Valuable intermediates in the synthesis of oligonucleotides. Tetrahedron Lett. 27, 469-472 and the like.

In addition, a synthesized polynucleotide used in the present invention would preferably be a short one in view of the amplification efficiency, for example, having 60 to 150mers, more preferably, 60 to 100mers. The number of the nucleotides of the synthesized polynucleotide in the present invention is not specifically limited, and may be in the range of 60 to 200, preferably, 60 to 100.

(Nucleic Acid Quantitative Kit)

The kit for quantifying nucleic acid used in the present invention comprises a synthesized polynucleotide as the above standard preparation, and may further comprise at least a pair of primers corresponding to a target nucleic acid, a probe corresponding to a target nucleic acid, DNA polymerase, buffer, and the like. These kits may comprise, for example, a reagent catalyzing a synthesis of primer extension products, nucleoside triphosphate of a substrate, and implements used as indicators (for example, if the indicator is biotin, an adipin-enzyme conjugate, the substrate of the enzyme, and chromogen), buffer suitable for the reaction of PCR or hybridization, if necessary.

The phrase "pair of primers corresponding to a target nucleic acid" used in the present invention means a pair of primers consisting of a first primer which is complementary or substantially complementary to one strand of the exon region of a sequence of a target gene (or a gene sequence encoding a target mRNA) and a second primer which is complementary or substantially complementary to the exon region of the target gene sequence on other strand. The exon region between the first primer and the second primer is amplified.

In the present invention, a target nucleic acid is amplified using at least a pair of these primers.

Those skilled in the art can easily design pairs of primers to amplify a target nucleic acid or pairs of primers to amplify a standard preparation on the basis of the target nucleic acid (for example, Genome Res. 1996 Oct ; 6 (10) : 986-94 reference).

For example, if hMOR1 cDNA is selected as a target nucleic acid, a complementary sequence to the 1129th to 1210th base of hMOR1 cDNA (SEQ ID NO:1) can be used as a standard preparation by chemical synthesis. In this case, 5'-CCTTGGTTACAATCCCAGAACTAC-3' (SEQ ID NO: 2) is used as an upstream primer and 5'-AGGCAGCTGTTTGTGTAACCTAGA-3' (SEQ ID NO:3) as a downstream primer.

It is easy for those skilled in the art to design a probe corresponding to a synthesized polynucleotide used in the present invention or a probe corresponding to a synthesized probe which is a standard preparation according to a target sequence (for example, Genome Res. 1996 Oct ; 6 (10) : 986-94 reference). For example, a probe corresponding to a target nucleic acid is a probe consisting of a nucleic acid of the region between the first primer and the second primer in the target nucleic acid. A primer corresponding to a synthetic polynucleotide is a probe consisting of a nucleic acid of the region between the first primer and the second primer. An adequate oligonucleotide

probe used in the present invention would preferably have about 15 to about 50 nucleotides, and more preferably about 25 to about 35 nucleotides. An oligonucleotide probe can be labeled by incorporating chemical substances and the like that are detectable by biochemical, immunochemical, or chemical means. Some useful indicators include
5 radioisotopes of P^{32} or the like; fluorescent substances such as fluorescamine, fluorescein isothio-cyanate; luminescent substances such as luminal or luciferin; enzymes such as β -galactosidase, peroxidase, alkaliphosphatase; biotin, antibodies and the like. In particular, preferred are fluorescent probes labeled by fluorescent substances or phosphorylated probes labeled by P^{32} .

10 The DNA polymerases used in the present invention are listed as thermostable DNA polymerases having reverse transferase activity and $5' \rightarrow 3'$ exonuclease activity, for example, Tth DNA polymerase and the like.

In the present invention, known or commercially available buffers may be used (for example, buffer produced by PEB isosystems; Genome Res. 1996 Oct. ; 6(10) : 986-94
15 reference).

In addition, the amount of each reagent that is comprised in the quantitative kit is appropriately determined according to the amount of a sample or kind of a target nucleic acid.

The more preferable embodiment of the present invention provides a kit for
20 quantifying nucleic acid to quantify multiple target nucleic acids, wherein each amplification reagent comprising a pair of primers corresponding to a target nucleic acid is loaded at each of multiple reaction sites (preferably, each reaction site of a reactor having multiple reaction sites), and an amplification reagent comprising the standard preparation of any one of claims 1 to 4 and a pair of primers corresponding to the
25 standard preparation is loaded at a reaction site which is not loaded with a pair of primers corresponding to the target nucleic acid. It is possible to detect the presence or absence of multiple target nucleic acids or the amount thereof in a sample in a single procedure by using this quantitative kit.

The multiple reaction sites are not specifically limited as far as there are two or more
30 reaction sites, generally, 2 to tens of thousands, preferably, 2 to 1,000, more preferably 10 to 800, even more preferably, 10 to 300 reaction sites.

In this embodiment, a reactor having multiple reaction sites is used. Each reaction of a sample that may comprise a target nucleic acid with each amplification reagent, and each of standard preparations consisting of a synthesized nucleotide set up in successive
35 prescribed concentrations with each amplification reagent are carried out at each reaction

site. The concentration of the standard preparation is not particularly limited, but preferably is in the range of 10^1 copies to 10^7 copies or more in each container. Each amplification reagent comprises a pair of primers capable of amplifying a target nucleic acid, or the synthesized polynucleotide, respectively. The reactor used herein is not particularly limited by the configuration and structure of the reactor as long as there are two or more reaction sites so that a sample and each amplifying reagent can react in a single procedure. Preferably, the reactors used in the present invention include, for example, a plate having multiple wells, a reactor having multiple slide glasses, a reactor having multiple test tubes and the like. In view of the experiment space, operability, or the like, preferably, a plate having multiple wells can be used. The numbers of the wells of these plates are determined by the numbers of the reagents. Preferred are commercial 96-well plates and 384-well plates. However, any reactors that have the desired number of reaction sites according to the numbers of reagents can be used.

Since the number of amplification reagents is regulated only according to the number of target nucleic acids, there is no limit to their number: for example, one could have a quantitative kit comprising a standard preparation consisting of 10 to 800 kinds of amplification reagents and synthetic oligonucleotides for the targets provided. In another embodiment, a kit comprising the standard preparation consisting of 10 to 300 kinds of amplification reagents and a synthetic oligonucleotide for the target is given. If there are many amplification reagents, it is possible to divide the different sets of amplification reagents onto multiple plates (for example, on 2 to 10 plates) and carry out quantitative reactions several times.

(Method for Quantifying Nucleic Acids)

The method for quantifying nucleic acids is described below.

According to a method for quantifying a specific target nucleic acid of the present invention, amplification reagents comprising at least one pair of primers corresponding to each target nucleic acid are added to the sample. An amplification reagent comprising a pair of primers corresponding to the synthetic polynucleotide is added to the chemical synthetic polynucleotide as a standard preparation. Amplification reactions are carried out on both respectively, amounts of the standard preparation and the amplified target nucleic acid are measured, and the amount of the target nucleic acid before amplification is calculated according to those measurements.

[Sample and Target nucleic acid]

First, samples of this invention may comprise a target nucleic acid, and are not particularly limited. The samples of this invention include, for example, a tissue or mRNA sample derived from cultivated cells of human or other mammal (e.g. guinea pig, rat, mouse, rabbit, sheep, swine, bovine, feline, canine, monkey, etc.). Examples of such tissues used as samples might include: brain, brain regions (e.g., olfactory bulb, amygdaloid nucleus, cerebral basal bulb, hippocampus, thalamus, hypothalamus, subthalamus, cerebral cortex, medulla oblongata, cerebellum, occipital lobe, frontal lobe, temporal lobe, putamen, caudate nucleus, corpus callosum, substantia nigra), spinal cord, hypophysis, stomach, pancreas, kidney, liver, gonad, thyroid, gallbladder, bone marrow, adrenal gland, skin, muscle, lung, gastrointestinal tract (e.g., large intestine and small intestine), blood vessel, heart, thymus, spleen, submandibular gland, peripheral blood, peripheral hemocyte, prostate, testis, ovary, placenta, uterus, bone, joint, skeletal muscle, etc. By quantifying the target mRNA contained in the mRNA sample, it is possible to analyze the expression level of the target gene at the site where the mRNA is obtained.

Further, use of an mRNA sample derived from a patient having a specific disease allows easy characterization of a gene related to the disease (for example, GPCR gene). Particularly, in the case of identifying a G protein coupled receptor, tyrosine phosphatase receptor, ion channel, or other such genes associated with multiple-gene diseases such as a cancer, in which multiple genes seem to be related, the present invention is useful to characterize the related gene or protein. This is because the expression level of each gene can be measured by one quantitative operation.

By using the synthetic polynucleotide of the present invention as standard preparation for quantification or detection of specific target nucleic acid in a sample as described above, it is possible to (1) identify genes of which expression is characteristically increased or reduced in certain cells or tissues by quantitatively analyzing each expression level of multiple genes at the same time, and (2) identify a certain gene in a given gene family of which expression is characteristically increased or reduced in certain cells or tissues, by analyzing the expression of multiple genes belonging to that specific gene family at the same time and calculating the absolute value of the expression level of the gene.

The "multiple genes" are meant to signify two or more genes. There is no specific upper bound, within limits of feasibility, but the range is commonly two to several tens of thousands of genes, or preferably, two to 1,000 genes, or more preferably, 10 to 800 genes, or even more preferably, 10 to 300 genes.

"The expression level of a gene is characteristically increased or reduced" is meant, compared with the expression of a gene in normal cells or tissues, to refer to a physiologically significant difference in expression, whether small or large. The target nucleic acid family in the present invention is not specified, but for example, it could be selected from the gene family concerning the G protein coupled receptor gene family, tyrosine phosphatase receptor gene family, ion channel gene family, or transcription factor, transporter, protein kinase, protein phosphatase, protease, heat shock protein, ATPase or DNA-binding protein gene family or the like.

The calculation of the level of gene expression or absolute value of gene expression can be carried out according to the quantitative method using a target mRNA as described below.

Also, according to the present invention, use of DNA included in recombinant gene foods as the target nucleic acid may allow detection of recombinant gene foods or presence of recombinant genes in natural foods obtained without using recombinant gene techniques.

Currently known recombinant gene foods include soybean, potato, corn, tomato, papaya. Further, the recombinant genes in those foods and pairs of primers to detect them, general quantitative methods or the like are known. For example, they are disclosed in "JAS Analysis Handbook recombinant gene foods detection/ analysis manual quantitative PCR" (H13. April, published by Tokyo IAA Center for Food Quality, Labeling and Consumer Services).

For example, in the detection of corn CB351, a known pair of primers consists of 5'-CCT TCG CAA GAC CCT TCC TCT ATA-3' (SEQ ID NO:5) and 5'-GTA GCT GTC GGT GTA GTC CTC GT-3' (SEQ ID NO:6). For the detection of papaya 55-1, a known pair of primers consists of 5'-TTA CGG CGA GTT CTG TTA GG-3' (SEQ ID NO:7) and 5'-CAT GTG CCT GAG AAA TAG GC-3' (SEQ ID NO:8). For the detection of potato New Leaf Y, a known pair of primers consists of 5'-AAA AGA GCT GTC CTG ACA GC-3' (SEQ ID NO:9) and 5'-TCC TCC TGC ATC AAT TGT GT-3' (SEQ ID NO:10).

In another embodiment of the present invention, the target nucleic acid may be a G protein coupled receptor, tyrosine phosphatase receptor or ion channel coding gene DNA, or mRNA thereof. In this case, by reacting each amplification reagent comprising a pair of primers corresponding to the mRNA of a gene belonging to a family such as target G protein coupled receptor, tyrosine phosphatase receptor, ion channel receptor or the like with an mRNA sample at each reaction site of the reactor, carrying out amplification

reactions, and quantifying mRNA amplified products, it is possible to measure the expression level of a gene belonging to gene families such as the G protein coupled receptor, the tyrosine phosphatase receptor, the ion channel receptor gene family, or the like.

5 In another embodiment of the present invention, by completely preparing all pairs of primers corresponding to the mRNA of a gene belonging to given gene family such as all of the known G protein coupled receptor, tyrosine phosphatase receptor, ion channel receptor gene families, and the like, and reacting amplification reagents comprising those pairs of primers, respectively at each reaction site, it is possible to measure the degree of
10 production of each mRNA of the gene belonging to gene families such as the G protein coupled receptor, tyrosine phosphatase receptor, ion channel receptor gene families, and the like in an mRNA sample at the same time. Of course, it is also possible to carry out quantitative reactions several times by appropriately dividing the different sets of amplification reagents onto multiple plates when necessary.

15 In another embodiment of the present invention, by using a group of pairs of primers corresponding to the mRNA of a gene belonging to a family such as the G protein coupled receptor, tyrosine phosphatase, or the ion channel receptor gene family, with one quantitative manipulation, it is possible to characterize the gene belonging to gene families such as the G protein coupled receptor, tyrosine phosphatase receptor, or ion
20 channel receptor gene family highly expressed in the genes belonging to the gene families that include the group of G protein coupled receptors, tyrosine phosphatase receptors, ion channel receptors, and the like.

In addition, the following are currently known as G protein coupled receptors:

- (1) Acetylcholine receptors: M_1 ; M_2 ; M_3 ; M_4 ; M_5
- 25 (2) Adenosine receptors: A_1 ; A_{2A} ; A_{2B} ; A_3
- (3) Adrenoceptors: $\alpha 1A$; $\alpha 1B$; $\alpha 1D$; $\alpha 2A$; $\alpha 2B$; $\alpha 2C$; $\beta 1$; $\beta 2$; $\beta 3$
- (4) Angiotensin receptors: AT_1 ; AT_2
- (5) Bombesin receptors: BB_1 ; BB_2 ; bb_3
- (6) Bradykinin receptors: B_1 ; B_2
- 30 (7) Calcitonin, Aininin, CGRP, and Adrenomedullin receptors:
- (8) Cannabinoid receptors: CB_1 ; CB_2
- (9) Chemokine receptors: CCR_1 ; CCR_2 ; CCR_3 ; CCR_4 ; CCR_5 ; CCR_6 ; CCR_7 ; CCR_8 ; CCR_9 ; CCR_{10} ; $CXCR_1$; $CXCR_2$; $CXCR_3$; $CXCR_4$; $CXCR_5$; CX_3CR_1 ; XCR_1 ;
- (10) Chemotactic receptors : C_3a ; C_5a ; fMLP
- 35 (11) Cholecystokinin and Gastrin receptors: CCK_1 ; CCK_2

- (12) Corticotropin-releasing factor receptors: CRF₁; CRF₂
 - (13) Dopamine receptors: D₁; D₂; D₃; D₄; D₅
 - (14) Endothelin receptors: ET_A; ET_B
 - (15) Galanin receptors: GAL 1; GAL2; GAL3
 - 5 (16) Glutamate receptors: mgl₁; mgl₂; mgl₃; mgl₄; mgl₅; mgl₆; mgl₇; mgl₈
 - (17) Glycoprotein hormone receptors: FSH; LSH; TSH
 - (18) Histamine receptors: H₁; H₂; H₃; H₄
 - (19) 5-HT receptors: 5-HT_{1A}; 5-HT_{1B}; 5-HT_{1D}; 5-HT_{1B}; 5-HT_{1F}; 5-HT_{2A}; 5-HT_{2F}; 5-HT_{2C}; 5-HT₃; 5-HT₄; 5-HT_{5A}; 5-HT_{5B}; 5-HT₆; 5-HT₇
 - 10 (20) Leukotriene receptors: BLT; CysLT₁; CysLT₂
 - (21) Lysophospholipid receptors: edg₁; edg₂; edg₃; edg₄
 - (22) Melanocortin receptors: MC₁; MC₂; MC₃; MC₄; MC₅
 - (23) Melatonin receptors: MT₁; MT₂; MT₃
 - (24) Neuropeptide Y receptors: Y₁; Y₂; Y₄; Y₅; Y₆
 - 15 (25) Neurotension receptors: NTS₁; NTS₂
 - (26) Opioids: DOP; KOP; MOP; NOP
 - (27) P₂Y receptors: P₂Y₁; P₂Y₂; P₂Y₄; P₂Y₆; P₂Y₁₁; P₂Y₁₂
 - (28) Peroxisome proliferators: PPAR- α ; PPAR- β ; PPAR- γ
 - (29) Prostanoid receptors: DP; FP; IP; TP; EP₁; EP₂; EP₃; EP₄
 - 20 (30) Protease-activated receptors: PAR₁; PAR₂; PAR₃; PAR₄
 - (31) Somatostatin receptors: sst₁; sst₂; sst₃; sst₄; sst₅
 - (32) Tachykinin receptors: NK₁; NK₂; NK₃
 - (33) Thyrotropin-releasing hormone receptors: TRH₁; TRH₂
 - (34) Urotensin-II receptor:
 - 25 (35) Vasoactive intestinal peptide or pituitary adenylate cyclase activating peptide receptors: VPAC₁; VPAC₂; PAC₁
 - (36) Vasopressin or Oxytocin receptors: V_{1a}; V_{1b}; V₂; OT
- Additionally, the following are known as genes belonging to families such as tyrosine phosphatase receptor, ion channel receptor, or the like.
- 30 (37) Ion channel: Na⁺ channels (type I; type II/type IIA; type III; SCL/NaG; PN1; NaCh₆; NaDRG; SkM1/ μ 1, or SkM2), K⁺ channels (kv; EAG; KQT; IRK; ROMK; GIRK; K_{ATP} or the like), Ca²⁺ channels (α 1G; α 1E; α 1S; α 1C; α 1D; α 1B; α 1A; IP₃; ryanodine receptor or the like), Cl⁻ channels (GABA_A; GABA_C; glycine receptors; C1C0; C1C1; CFTR or the like), non-selective cation channels (nAChR; 5-HT₃; NMDA; AMPA; P_{2X}ATP; CNG, or the like) or the like.
 - 35

(38) Tyrosine phosphatase receptors: insulin receptor; EGF receptor; ~~or~~ the like.

The nucleic acid quantitative method used in the present invention is capable of using several kinds of applications other than function analysis of human GPCR, SNP analysis, or determination of recombinant gene foods. For example, it is possible to
5 diagnose specific diseases by using sets of multiple amplification reagents comprising a pair of primers detecting mRNA produced by the known disease gene. Because the present invention is capable of accurately measuring the expression level of each gene, it has an advantage in providing diagnoses more accurately than the known method.

10 [Amplification of Nucleic Acids]

In the quantitative method of the present invention, a target nucleic acid that may be contained in a sample is amplified by using amplifying reagents consisting of a pair of primers corresponding to the target nucleic acid. In the preferred embodiment of the present invention, amplification of a target nucleic acid may be carried out by the known
15 polymerase chain reaction (PCR) (see US Patent No. 4683195; US Patent No. 4683202; US Patent No. 1965188 and the others).

When the target is an mRNA, the amplification of the target mRNA may be carried out, for example, by first using viral reverse transcriptase to obtain a cDNA by reverse transcription of the target mRNA, and then amplifying the obtained cDNA. In a more
20 preferred embodiment of the present invention, the amplification of mRNA is carried out by using reverse transferase-polymerase chain reaction (RT-PCR)(US Patent No. 5310652; US Patent No. 5322770; US Patent No. 5561058; US Patent No.5641864; US Patent No.5693517)

In the present invention, many mRNA amplification methods can be used in
25 addition to the said polymerase chain reaction. These other amplification methods include, for example, the chain substitution assay method (US Patent No. 5455166 and other, reference), the transcription amplifying system (TAS) (see US Patent No. 5437990; No. 5409818; No. 5399491 and others), and the self-sustained sequence replication system (3SR) (WO92/08800 and others, see references), among others.

30 One skilled in the art would easily set the conditions of these amplifying reactions by varying the kinds of reagents used.

[Quantification of Target Nucleic Acid]

In the next step of the quantification method of the present invention, the amount of
35 amplified nucleic acid product created in the previous step is quantified. The

quantification of this amplified product is preferably carried out by a method using a probe. According to the preferred embodiment, the above method should be one using a probe labeled with fluorescent substance.

According to the more preferred embodiment of the present invention, the
5 quantification of target mRNA is carried out by the "TaqMan method" or "5' nuclease assay method" (see Proc. Natl. Acad. Sci. USA, vol.88, p7276-7280(1991); US Patent No. 5210015; No. 5487972; No. 5804375; No.5804375 and others). However, if necessary, the SYBER Green method, or some hybridization method may be used. In the TaqMan
10 assay method, a probe labeled at the 5' terminus is used. Also, this probe may be modified at the 3' terminus to prevent the probe from working as a primer to synthesize DNA. Examples of this modification could include the addition of a phosphate group or some fluorescent substance to the 3' terminus. Amplification of the target mRNA may be carried out by using a DNA polymerase having 5'→3' exonuclease activity, for example, Tth DNA polymerase. Any probes that hybridize downstream from the
15 abovementioned primer on the target mRNA are removed by the 5'→3' exonuclease activity of DNA polymerase during the amplification reaction. During each new amplification step of the target region, the probe is removed and the labeled substance (for example, phosphate group or fluorescent substance), with which the probe was modified, is released. By quantifying the amount of this released labeling substance, the
20 amount of target mRNA produced can be indirectly measured.

Known methods are used to detect the released target substance quantitatively. In the preferred method, the said probe is labeled at the 5' and 3' terminus by two fluorescent substances, and each substance has the ability to suppress the fluorescence of the other substance. While this probe is hybridized to template DNA, the fluorescence
25 emitted by the two substances is suppressed by their reciprocal activity upon each other. However, when the probe is removed by the 5'-3' exonuclease activity of the DNA polymerase, these substances will begin to fluoresce. This fluorescence is increased according to progress of the amplification reaction, and this increase in fluorescence is monitored.

[Drawing up the Calibration Curve and Calculating the Amount of target nucleic acid before Amplification]

The present invention provides prescribed amount of a synthesized polynucleotide as a standard preparation. Thus, a sample comprising a target nucleic acid can be
35 quantified based on the "calibration curve" drawn up after amplification of the standard

preparation.

A way of drawing up this calibration curve is disclosed, for example, in the publication of Japanese Patent No. H11-123095. To draw up the calibration curve, the amount of polynucleotide as the standard preparation produced in polymerase chain reaction is plotted as against varied known amounts of RNA present before amplification. In order to ensure a high level of accuracy, the calibration curve is drawn up by carrying out the amplification reaction using a series of dilutions that gradually change the concentration of the amplification reaction mixture. This calibration curve is drawn up by plotting the amount of internal standard preparation or the target nucleic acid amplified over a given number of amplification cycles.

The amount of the target nucleic acid before amplification is determined by comparing the amount of the amplified target nucleic acid with the above calibration curve. The standard preparation and a set of dilution series of target nucleic acid is amplified at another reaction site under the same conditions; the reaction is stopped at the exponential stage of amplification; and the amount of target nucleic acid present in this sample before the amplification is determined to be extrapolated according to the calibration curve drawn up by using the standard preparation.

[Method for Diagnosing a Disease and Medicine for Treating the Disease]

According to the above method (23) of the present invention, gene expression analysis may be carried out using mRNA sample derived from a patient. This expression analysis provides information that can be used to diagnose the patient by detecting the characteristic expression of a specific disease-related gene. In the present invention, by analyzing the gene expression of a specific disease-related gene family (particularly, the disease-related GPCR gene family of which genes are found in some patients), one can determine which gene among many is responsible for the characteristic gene expression in a single operation.

Therefore, a medicine comprising an agonist, antagonist, antibody against the gene product of the specified gene, or a DNA coding for the gene product may be particularly effective for patients that are the subject of such a diagnosis. The present invention makes it possible to specify plural abnormally expressed genes and even to quantify with accuracy the expression level of those genes. Therefore, it is possible to select plural agonists, antagonists, or antibodies as an adequate prescription for the patient and to adjust the amount of this prescription according to the patient's expression level of the disease-related gene. That is, the present invention allows preparation of a tailor-made

medicine that will be prescribed specifically for the patient.

More specifically, for example, the following treatments may be effective in a patient who cannot expect a physiological function of a ligand to a certain receptor protein because of reduced levels of the receptor protein (as in the case of a patient with a deficiency syndrome of the receptor protein). It is possible to increase the amount of this receptor protein in the patient to ensure sufficient activities of the ligand by ① administering said receptor protein to the patient by prescribing a sufficient amount of the receptor protein, ② either (i) administering a DNA of the present invention coding for the needed receptor protein to the patient, and expressing the DNA, or (ii) implanting a cell within the patient after inserting a DNA coding for the receptor protein into the desired cell and expressing the DNA.

The medicine of the present invention is effective in the preservation or treatment of a disease related to a specified gene, for example, diseases of the central nervous (for example, Alzheimers disease, dementia, eating disorders, or the like), endocrinopathy (for example, hypertension, abnormal gonadal function, abnormal thyroid function, abnormal pituitary function, or the like), metabolic disease (for example, diabetes, lipidosis, hyperlipidemia or the like), cancer (for example, non-parvicellular lung cancer, ovarian cancer, prostate cancer, stomach cancer, urinary bladder cancer, breast cancer, cervical cancer, colon cancer, rectal cancer, or the like).

When a gene product of a gene specified by the present invention (for example, receptor protein), an agonist, antagonist or antibody thereto, or a DNA encoding the gene, is used as a prophylactic/therapeutic agent as mentioned above, a pharmaceutical preparation can be prepared in a conventional manner.

On the other hand, where the DNA encoding the protein of the present invention (hereinafter sometimes referred to as the DNA of the present invention) is used as a prophylactic/therapeutic agent as described above, the DNA itself is administered; alternatively, the DNA is inserted into an appropriate vector such as a retrovirus vector, adenovirus vector, adenovirus-associated virus vector, etc. and then administered in a conventional manner. The DNA of the present invention may also be administered as naked DNA, or with adjuvants to assist its uptake by gene gun or through a catheter such as a catheter with a hydrogel.

For example, ① the medicine of the present invention can be used orally, for example, in the form of tablets which may be sugar coated if necessary, capsules, elixirs, microcapsules etc., or parenterally in the form of injectable preparations such as a sterile

solution and a suspension in water or with another pharmaceutically acceptable liquid. These preparations can be manufactured by mixing ① the protein of the present invention with a physiologically acceptable known carrier, a flavoring agent, an excipient, a vehicle, an antiseptic agent, a stabilizer, a binder, etc. in a unit dosage form required in a generally
5 accepted manner that is applied to making pharmaceutical preparations. The effective component in the preparation is controlled in such a dose that an appropriate dose is obtained within the specified range given.

Additives miscible with tablets, capsules, etc. include a binder such as gelatin, corn starch, tragacanth and gum arabic, an excipient such as crystalline cellulose, a swelling
10 agent such as corn starch, gelatin and alginic acid, a lubricant such as magnesium stearate, a sweetening agent such as sucrose, lactose and saccharin, and a flavoring agent such as peppermint, Gaultheria adenoithrix oil, and cherry. When the unit dosage is in the form of capsules, liquid carriers such as oils and fats may further be used together with the additives described above. A sterile composition for injection may be formulated by
15 conventional procedures used to make pharmaceutical compositions, e.g., by dissolving or suspending the active ingredients in a vehicle such as water for injection with a naturally occurring vegetable oil such as sesame oil and coconut oil, etc. to prepare the pharmaceutical composition. Examples of an aqueous medium for injection include physiological saline and an isotonic solution containing glucose and other auxiliary agents
20 (e.g., D-sorbitol, D-mannitol, sodium chloride, etc.) and may be used in combination with an appropriate dissolution aid such as an alcohol (e.g., ethanol or the like), a polyalcohol (e.g., propylene glycol and polyethylene glycol), a nonionic surfactant (e.g., polysorbate 80TM and HCO-50), etc. Examples of the oily medium include sesame oil and soybean oil, which may also be used in combination with a dissolution aid such as benzyl benzoate
25 and benzyl alcohol.

The prophylactic/therapeutic agent described above may further be formulated with a buffer (e.g., phosphate buffer, sodium acetate buffer, etc.), a soothing agent (e.g., benzalkonium chloride, procaine hydrochloride, etc.), a stabilizer (e.g., human serum albumin, polyethylene glycol, etc.), a preservative (e.g., benzyl alcohol, phenol, etc.), an
30 antioxidant, etc. The thus-prepared liquid for injection is normally filled in an appropriate ampoule.

Since the thus obtained pharmaceutical preparation is safe and low toxic, the preparation can be administered to humans or mammals (e.g., rats, rabbits, sheep, swine, bovine, cats, dogs, monkeys, etc.).

The dose of the medicine of the present invention varies depending on the subject to which it will be administered, target organs, conditions, routes for administration, etc.; in oral administration, e.g., an adult patient, the dose is normally about 0.1 mg to about 100 mg, preferably about 1.0 to about 50 mg, and more preferably about 1.0 to about 20 mg per day (for 60 kg body weight). In parenteral administration, the single dose varies depending on the subject to which it will be administered, target organ, conditions, routes for administration, etc., but it is desirable, e.g., for an adult patient, to administer the active ingredient intravenously in a daily dose of about 0.01 to about 30 mg, preferably about 0.1 to about 20 mg, and more preferably about 0.1 to about 10 mg (for 60 kg body weight). For other animal species, the corresponding dose as converted per 60 kg body weight can be administered.

(Denotation of Abbreviations)

In the specification and drawings, the codes of bases, amino acids, compound and others are denoted in accordance with the IUPAC-IUB Commission on Biochemical Nomenclature or by the common codes in the art, examples of which are shown below. For amino acids that may have the optical isomer, L form is presented unless otherwise indicated.

DNA : Deoxyribonucleic acid
cDNA : Complementary deoxyribonucleic acid
A : Adenine
T : Thymine
G : Guanine
C : Cytosine
RNA : Ribonucleic acid
mRNA: Messenger ribonucleic acid
dATP : Deoxyadenosine triphosphate
dTTP : Deoxythymidine triphosphate
dGTP : Deoxyguanosine triphosphate
dCTP : Deoxycytidine triphosphate
ATP : Adenosine triphosphate
EDTA : Ethylenediamine tetraacetic acid
SDS : Sodium dodecyl sulfate
Gly: Glycine

	Ala: Alanine
	Val: Valine
	Leu: Leucine
	Ile: Isoleucine
5	Ser: Serine
	Thr: Threonine
	Cys: Cysteine
	Met: Methionine
	Glu : Glutamic acid
10	Asp : Aspartic acid
	Lys : Lysine
	Arg : Arginine
	His : Histidine
	Phe : Phenylalanine
15	Tyr : Tyrosine
	Trp : Tryptophan
	Pro : Proline
	Asn : Asparagine
	Gln : Glutamine
20	pGlu : Pyroglutamic acid
	Tos : P-toluenesulfonyl
	CHO : Formyl
	Bzl : Benzyl
	Cl ₂ Bzl: 2,6-dichlorobenzyl
25	Bom : Benzyloxymethyl
	Z : Benzyloxycarbonyl
	Cl-Z : 2-chlorobenzyloxycarbonyl
	Br-Z : 2-bromobenzyloxycarbonyl
	Boc : T-butoxycarbonyl
30	DNP : Dinitrophenol
	Trt : Trityl
	Bum : T-butoxymethyl
	Fmoc : N-9-fluorenylmethoxycarbonyl
	HOBt : 1-hydroxybenzotriazole
35	HOObt: 3,4-dihydro-3-hydroxy-4-oxo-1,2,3-benzotriazine

HONB : 1-hydroxy-5-norbornene-2,3-dicarboximide

DCC : N,N'-dicyclohexylcarbodiimide

The sequence identification numbers in the sequence listing of the specification
5 indicates the following sequence, respectively.

[SEQ ID NO:1]

This shows the base sequence of h MOR1.

[SEQ ID NO:2]

This shows the base sequence of an up stream primer N-917F used in Example 1.

10 [SEQ ID NO:3]

This shows the base sequence of a down stream primer N-998R used in Example 1.

[SEQ ID NO:4]

This shows the base sequence of probe N-945T used in Example 1.

[SEQ ID NO:5]

15 This shows the base sequence of primer for detection of corn CB351.

[SEQ ID NO:6]

This shows the base sequence of primer for detection of corn CB351.

[SEQ ID NO:7]

This shows the base sequence of primer for detection of papaya 55-1.

20 [SEQ ID NO:8]

This shows the base sequence of primer for detection of papaya 55-1.

[SEQ ID NO:9]

This shows the base sequence of primer for detection of potato New Leaf Y.

[SEQ ID NO:10]

25 This shows the base sequence of primer for detection of potato New Leaf Y.

EXAMPLES

The present invention is described in detail below with reference to EXAMPLES,
which are not deemed to limit the scope of the present invention.

30

EXAMPLE 1

(1) Drawing up the calibration curve for chemically synthesized DNA encoding a partial
sequence of hMOR1

This example describes drawing up the calibration curve for chemically
35 synthesized DNA encoding a partial sequence of hMOR1 cDNA (SEQ ID NO:1 :

GenBank accession number L25119) by TaqMan method.

(2) Samples

The amplification was carried out using serial dilution solution of the chemically synthesized DNA encoding a partial sequence of hMOR1 cDNA (hMOR1T/M). The sequence of hMOR1COM of the present invention corresponds to the complementary sequence from the 1129th to the 1210th bp of hMOR1 cDNA. After synthesis by β -cyanoethylphosphoamidaide solid-synthesis method (chemical synthesis method), ammonia cleavage treatment was carried out, followed by purification by polyacrylamide modified gel electrophoresis.

(3) Amplification primers and detection probes

The amplification of hMOR1 cDNA partial sequence region was carried out by using up stream primer N-917F having the sequence 5'-CCTTGGTTACAATCCCAGAACTAC-3' (SEQ ID NO:2), and down stream primer N-998R having the sequence 5'-GCAGCTGTTTGTGTAACTAGA-3' as a pair of primers.

The above up stream primer, N-917F hybridizes the complementary sequence from the 1129th-1153th bp of hMOR1 cDNA (SEQ ID NO:1). The above down stream primer, N-998R hybridizes the sequence from the 1187th-1210th bp of hMOR1 cDNA (SEQ ID NO:1). These primers catalyze the amplification of an 82 base pair product comprising one part of the entire length of the hMOR1 cDNA sequence.

The detection was carried out by using N-945T, having 5'-CCAGACTGTTTCTTGGCACTTCTGCATTG-3' (SEQ ID NO:4) as a probe. This probe hybridizes to the complementary sequence from the 1157th -1185th bp of hMOR1 cDNA (SEQ ID NO:1).

In order to make it possible to carry out the detection with the TaqMan method, the above probe was labeled with a fluorescein type fluorescent dye (FAM: reporter) at the 5' terminal and a rhodamine type fluorescent dye (TAMRA: quencher) at the 3' terminal.

In the labeled probe, the fluorescence of the reporter is suppressed when it does not hybridize, because of a migration phenomenon of fluorescent resonant energy. To prevent extension of the above probe by DNA polymerase during amplification, the 3' terminal of the above probe is blocked with a phosphoric acid.

(4) Amplification

Each PCR amplification was carried out with a total reaction amount of 20 μ l using TaqMan™ Universal PCR Master MIX (Applied Bio Systems Japan Co. Ltd.). The following is the final reagent concentration : sample gene, 1 \times TaqMan™ Universal PCR Master MIX (comprising AmpliTaq Gold™ DNA polymerase, AmpErase™
5 Urasil-N-glycosylase (UNG), ROX and others), 900nM of each primer, 200nM of probe.

The amplification reaction was carried out with ABI PRISM (trade mark) 7900HT sequence detection system (Applied Bio Systems Japan Co. Ltd.). The following is a profile of the thermal cycle used.

The time and temperature of the thermal cycle and the incubation in Amp Erase
10 UNG reaction : two minutes at 50 °C, activation of the AmpliTaq Gold DNA polymerase : ten minutes at 95°C, denaturation/annealing/extension : 40 cycles : 15 seconds at 95°C, 1 minute at 60°C.

(5) Quantitative TaqMan Analysis

15 In the TaqMan analysis, during amplification, the probe hybridizing to the above target sequence is hydrolyzed from the 5' terminal by 5'-3' exonuclease reaction by the above DNA polymerase. Then, the reporter fluorescent dye is released and the fluorescence intensity increases.

The stored amplified product was quantified by measuring the increase of
20 fluorescent intensity of the reporter dye in the reaction solution. At the same time, the fluorescent intensity of the fluorescent reference (fluorescent dye: ROX) was also measured to determine experimental error in the reaction solution. During each amplification cycle, the above reporter fluorescent dye and reference dye excite at the wavelength of light near the greatest excitation. Emission of the above reporter
25 fluorescent dye and reference fluorescent dye are measured at the time of the greatest emission. This frequency is determined by the ABI PRISM™ 7900HT sequence detection system in advance. If another detection instrument is used, then an adequate frequency should be selected.

The value of the fluorescence was analyzed by 7900HT SDS software (Applied Bio
30 Systems Japan Co. Ltd.). First, the fluorescent intensity of the reporter fluorescent dye was standardized by a reference fluorescent dye, and then a standardized reporter signal (Rn) was calculated. Then, the value calculated as being the average value (baseline) of relatively constant Rn during each cycle of the PCR primary cycle was designated as Δ Rn. When the amplification curve was plotted, the cycle number which analysis
35 algorithm detected an increase of Δ Rn to the number of cycles, an increase of fluorescent

signal (ΔR_n) corresponding to an exponential amplification of the amplification product for the first time was designated as the Threshold Cycle (C_T). In particular, in order to determine the C_T , PCR primary cycles (3-15 cycles) that are not considered to have achieved exponential amplification of the amplification product were used as a baseline, and the standard deviation of an average ΔR_n in this cycle was calculated. Then, the value of this standard deviation was multiplied ten times and defined as the "Threshold". The cycle number corresponding to this Threshold value on each amplification curve was defined as C_T .

During the period of exponential amplification of the above amplification product, the C_T is proportional to the logarithm of the first target copy number. Accumulation of the amplification product in the later stage cycles inhibits the reaction and at last leads to the plateau of the reaction.

(6) Results

The following are C_T values obtained from each sample. Each C_T represents the average obtained from four reactions.

Sample	C_T value
10^7 copies of hMOR1T/M	16.3
10^6 copies of hMOR1T/M	19.2
10^5 copies of hMOR1T/M	22.5
10^4 copies of hMOR1T/M	26.0
10^3 copies of hMOR1T/M	29.2
10^2 copies of hMOR1T/M	32.9
0 copy of hMOR1T/M	above 40.0

The calibration curve was prepared using the C_T value obtained from the amplification of a known amount of template hMOR1COM (standard sample). In particular, the calibration curve was drawn up by plotting C_T against this known primary amount of standard sample (logarithm value). For an approximated curve, the following linear equation was used.

$$C_T = (\text{Log} [\text{DNA}]_T - \text{Log} [\text{DNA}]_0) / \text{Log}(1+e)$$

(wherein $[\text{DNA}]_0$ is a primary concentration, $[\text{DNA}]_T$ is a concentration of an amplification product at a C_T cycle, e is an average amplification efficiency, and $\text{Log}(X)$ is a logarithm where X represents a base of log 10). The 7900HT SDS software was used to determine parameters.

By using the value of C_T obtained from samples, the following calibration curve was obtained:

$$C_T = 39.34 - 3.331 \times \text{Log} [\text{DNA}]_0$$

Correlation coefficient $R^2 = 0.999$

5 Average amplification efficiency $e = 99.6\%$

EXAMPLE 2

(1) Extraction of RNA and synthesis of DNA

Prostate cancer cells (LNCaP-FGC cells) were cultured until confluent. After
10 removing the cells with 0.25% trypsin-1mM EDTA (Invitrogen Co. Ltd.) and counting the number of cells, total RNA was extracted and purified according to the manual instructions of the RNeasy mini KIT (QUAGEN Co. Ltd.). The first strand cDNA was synthesized from the extracted RNA according to the manual instructions of the SuperScript II (Invitrogen Co. Ltd.), and after ethanol precipitation, the cDNA was eluted
15 and used as below. Synthesized cDNA was dissolved in TE to correspond to 10 mg/ml RNA and diluted to correspond to 5 ng/ μ l in TE comprising 50 μ g/ml yeast tRNA. Five (5) μ l of diluted cDNA solution (corresponding to 25 ng of RNA) was used as a measuring sample for a quantification of mRNA of one kind of GPCR.

20 (2) Quantification of GPCR mRNA using chemical synthesized standard preparation

Based upon the known sequences of 160 kinds of GPCRs, primers and probes were designed using Primer Express™ software (Applied Bio Systems Japan Co. Ltd.). Further, (-) strand DNA having a sequence between the primers was chemically synthesized. After diluting chemically synthesized DNA to 10^6 copies / 5 μ l with TW
25 comprising 50 μ g/ml yeast tRNA, dilution series were prepared until a concentration of 10^2 copies / 5 μ l each were achieved at 10x. The measurement of one kind of GPCR mRNA was carried out by dispensing 5 μ l of each of five kinds of dilution series of those chemically synthesized products and one of the above measuring samples by duplex. As the amplification reagents, TaqMan™ Universal PCR Master kit (Applied Bio Systems
30 Japan Co. Ltd.) and the above designed TaqMan™ Probe Kit (Applied Bio Systems Japan Co. Ltd.) were used. After preparing an amount of 15 μ l solution of the amplification reagents, those solutions were added to each well containing the above standard preparation or the measuring sample. The final concentration of each primer and probe was adjusted according to manual instructions. TaqMan™ PCR was carried out by ABI
35 PRISM™ 7900HT sequence detection system (Applied Bio Systems Japan Co. Ltd.),

using the thermal cycles described in the manual of TaqMan™ universal-PCR Master Mix (Applied Bio Systems Japan Co. Ltd.)

The quantitative TaqMan analysis of the amplification product was carried out by 7900HT SDS software (Applied Bio Systems Japan Co. Ltd.). Using the above
5 conditions, quantitative measurement of the 32 kinds of GPCR was carried out in one well of a 384-well plate. Use of five plates of a 384-well plate allowed accurate quantification of all the aforementioned 160 GPCRs expressed in the prostate cancer cell strain (LNCaP-FGC cells).

10 Industrial Applicability

The standard preparation of the present invention is a synthetic polynucleotide with the advantage that a desired sequence can accurately be obtained by a concise method compared to the standard preparation consisting of a polynucleotide obtained by conventional biosynthesis. Further, the standard preparation of the present invention is
15 not biologically contaminated. Thus, the standard preparation of the present invention is safe for the environment, and has the additional advantage of reducing factors that inhibit highly accurate quantification.

Moreover, when a single strand polynucleotide is used as the standard preparation, the quantitative method and the quantitative kit of the present invention allow more
20 accurate quantification because of similarity of the standard used to substance to be quantified.

Furthermore, the other embodiment of the quantitative method and the quantitative kit of the present invention can, with a single manipulation, detect with high-sensitivity an amount of the multiple target nucleic acids in samples that may contain multiple
25 target nucleic acids. Therefore, the present invention provides a system that can carry out expression analysis of the target nucleic acid with high-sensitivity.

Furthermore, the quantification method and quantification kit of the present invention make it possible to diagnose specific diseases and examine genetically modified foods to determine if recombinant DNA is present.

30

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.